Tilray Logo
US88688T1007
A2JQSC
TLRY

Tilray

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 57,39 € (+1535,04%). La mediana è 36,64 € (+943,87%).

Acquista
  5
Mantieni
  13
Vendi
  2

  • Tilray invests £50m in BrewDog to improve beers, pubs and working conditions

    Tilray, which bought BrewDog in March for £33m after the brewer entered administration, is investing more than £50m to improve beer quality, reopen and upgrade selected bars, raise pay and improve working conditions. The company is upgrading the Aberdeenshire brewery, launching new beers, introducing US craft lines into BrewDog venues and considering further UK craft acquisitions. Administrators said creditors will not be repaid in full and crowdfunding shares were rendered worthless, though some investor benefits and supplier continuity have been maintained. » Altro su theguardian.com


  • Tilray positioned to benefit if Trump advances marijuana rescheduling

    A federal appeals court refused to pause the Biden administration's move to consider broader rescheduling of marijuana, keeping alive a proposal to reclassify cannabis to Schedule III. Schedule III would not legalize recreational use or interstate commerce but could ease research and expand medical opportunities that would help Tilray's international medical cannabis business. Tilray reported record fiscal 2026 revenue, sharply improved cash flow and near-elimination of net debt, and management sees U.S. rescheduling as a future growth opportunity. Legal challenges and timing remain uncertain, so potential investors should view rescheduling as upside rather than a guaranteed catalyst. » Altro su finance.yahoo.com


  • Tilray Brands posts record fiscal 2026 revenue but shares fail to rally

    Tilray Brands reported record fiscal 2026 revenue of about $915 million and an 11% rise in adjusted EBITDA to $61.1 million, with adjusted net income nearly doubling to $12.2 million. The results nonetheless missed sell-side forecasts and the company recorded a GAAP net loss of $49.6 million. Management guided to modest adjusted EBITDA growth for fiscal 2027 and has reduced debt largely through dilutive debt-for-equity swaps, while cannabis now represents only 29% of sales, leaving investors hesitant to drive the stock higher. » Altro su finance.yahoo.com

Nel 2022, Tilray ha già distribuito 0,10 € di dividendi. L'ultimo pagamento è avvenuto a giugno 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Tilray ha registrato ricavi pari a 241,83 Mln € e un utile netto di -42,55 Mln €
(EUR) maggio 2026
YoY
Ricavi 241,83 Mln 10,93%
Utile lordo 72,39 Mln 11,49%
Utile netto -42,55 Mln 97,24%
EBITDA 12,75 Mln 100,78%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
370,21 Mln €
Numero di azioni
111,83 Mln
Massimo/minimo a 52 settimane
20,48 € - 3,24 €
Dividendi No
Beta
1,92
Rapporto P/E
-2,81
Rapporto PEG
-0,02
Rapporto P/B
0,26
Rapporto P/S
0,36

Profilo aziendale

Tilray Brands Inc. beschäftigt sich mit der Forschung, dem Anbau, der Produktion, dem Marketing und dem Vertrieb von medizinischen Cannabisprodukten. Das Unternehmen ist in fünf Segmenten tätig: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, und Business Under Development. Das Unternehmen bietet medizinische und für Erwachsene bestimmte Cannabisprodukte, pharmazeutische und Wellness-Produkte, alkoholische Getränke sowie hanfbasierte Lebensmittel und andere Wellness-Produkte an. Es bietet seine Produkte Einzelhändlern, Großhändlern, Patienten, Ärzten, Apotheken, Kliniken, Krankenhäusern, Regierungen und Forschern an. Das Unternehmen betreibt Tilray Medical, eine medizinische Plattform, die GMP-zertifizierte Blüten, Öle, Vapes, Esswaren und topische Produkte anbietet. Es hat Niederlassungen in Kanada, den Vereinigten Staaten, Europa, Australien, Neuseeland, Lateinamerika und international. Das Unternehmen war früher unter dem Namen Tilray, Inc. bekannt. Tilray Brands Inc. wurde im Jahr 2018 gegründet und hat seinen Hauptsitz in New York, New York.

Nome
Tilray
CEO
Irwin David Simon
Sede centrale Leamington, on
Stati Uniti
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
19/07/2018
Dipendenti 3595

Simboli di borsa

Borsa Simbolo
NASDAQ
TLRY
Toronto Stock Exchange
TLRY.TO
XETRA
2HQ.DE
Frankfurt
2HQ.F
Düsseldorf
2HQ.DU
Hamburg
2HQ.HM
SIX
2HQ.SW
München
2HQ.MU
Wien
TLRY.VI
🍪

Parqet  usa i cookie. Scopri di più